Label-Free Enrichment of Highly Metastatic Tumor-Initiating Cells up to a Monoclonal State
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Cancer Cells and Metastasis · Cancer Research and Treatments · Monoclonal and Polyclonal Antibodies Research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Chemistry, Pohang University of Science and Technology, Pohang 37673, Republic of Korea.
SenPro Inc., Pohang University of Science and Technology, Pohang, Gyeongbuk 37673, Republic of Korea.
New Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation (K-MEDIhub), Daegu 41061, Republic of Korea.
Department of Convergence I.T. Engineering, Pohang University of Science and Technology (POSTECH), Pohang 37673, Republic of Korea.
Funding
Institute for Basic Science · National Research Foundation of Korea · the Ministry of Education Korea · Korea Technology and Information Promotion Agency for SMEs
References (50)
Show source-provided references
1. 10.1016/j.stem.2010.08.00910.1016/j.stem.2010.08.009 ↗
2. Qureshi-Baig K, Ullmann P, Haan S, Letellier E. Tumor-initiating cells: A criTICal review of isolation approaches and new challenges in targeting strategies. Mol Cancer. 2017;16(1): Article 40.10.1186/s12943-017-0602-2 ↗
3. Klarmann GJ, Hurt EM, Mathews LA, Zhang X, Duhagon MA, Mistree T, Thomas SB, Farrar WL. Invasive prostate cancer cells are tumor initiating cells that have a stem cell-like genomic signature. Clin Exp Metastasis. 2009;26(5):433–446.10.1007/s10585-009-9242-2 ↗
4. 10.1158/1535-7163.MCT-12-000210.1158/1535-7163.MCT-12-0002 ↗
5. Zhu X, Li L, Tang J, Yang C, Yu H, Liu K, Zheng Z, Gu X, Yu Q, Xu F-J, et al. Cascade-responsive nano-assembly for efficient photothermal-chemo synergistic inhibition of tumor metastasis by targeting cancer stem cells. Biomaterials. 2022;280: Article 121305.10.1016/j.biomaterials.2021.121305 ↗
6. Rattan R, Ali Fehmi R, Munkarah A. Metformin: An emerging new therapeutic option for targeting cancer stem cells and metastasis. J Oncol. 2012;2012: Article 928127.10.1155/2012/928127 ↗
7. 10.1016/j.cell.2011.11.05010.1016/j.cell.2011.11.050 ↗
8. 10.1016/j.omtn.2017.10.00110.1016/j.omtn.2017.10.001 ↗
9. 10.1038/onc.2010.20710.1038/onc.2010.207 ↗
10. Dylla SJ, Beviglia L, Park I-K, Chartier C, Raval J, Ngan L, Pickell K, Aguilar J, Lazetic S, Smith-Berdan S, et al. Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy. PLOS ONE. 2008;3(6): Article e2428.10.1371/journal.pone.0002428 ↗
11. Wang P, Gao Q, Suo Z, Munthe E, Solberg S, Ma L, Wang M, Westerdaal NAC, Kvalheim G, Gaudernack G. Identification and characterization of cells with cancer stem cell properties in human primary lung cancer cell lines. PLOS ONE. 2013;8(3): Article e57020.10.1371/journal.pone.0057020 ↗
12. 10.3390/cancers302210610.3390/cancers3022106 ↗
13. 10.1016/j.stem.2011.01.00710.1016/j.stem.2011.01.007 ↗
14. 10.1021/jacs.9b0606810.1021/jacs.9b06068 ↗
15. Balla MMS, Yadav HD, Pandey BN. Tumorsphere assay provides a better in vitro method for cancer stem-like cells enrichment in A549 lung adenocarcinoma cells. Tissue Cell. 2019;60:21–24.10.1016/j.tice.2019.07.003 ↗
16. 10.1111/j.1750-3639.2010.00379.x10.1111/j.1750-3639.2010.00379.x ↗
17. 10.1007/s10911-012-9255-310.1007/s10911-012-9255-3 ↗
18. 10.1021/acscentsci.8b0031310.1021/acscentsci.8b00313 ↗
19. 10.1007/s10529-013-1393-110.1007/s10529-013-1393-1 ↗
20. 10.1101/gad.106180310.1101/gad.1061803 ↗
21. Johnson S, Chen H, Lo PK. In vitro tumorsphere formation assays. Bio Protoc. 2013;3(3): Article e325.10.21769/BioProtoc.325 ↗
22. 10.1002/anie.20171292010.1002/anie.201712920 ↗
23. Lee YA, Lek CCJ, Rong G, Wu Z, Shathishwaran S, Lee JH, Tam WL, Wuestefeld T, Park SJ, Jung S, et al. Theranostics application of tumor-initiating cell probe TiY in non-small cell lung cancer. Theranostics. 2023;13(4):1370–1380.10.7150/thno.79282 ↗
24. Bahmad HF, Cheaito K, Chalhoub RM, Hadadeh O, Monzer A, Ballout F, El-Hajj A, Mukherji D, Liu YN, Daoud G, et al. Sphere-formation assay: Three-dimensional in vitro culturing of prostate cancer stem/progenitor sphere-forming cells. Front Oncol. 2018;8: Article 347.10.3389/fonc.2018.00347 ↗
25. Zhou X, Wang G, Sun Y. A reliable parameter to standardize the scoring of stem cell spheres. PLOS ONE. 2015;10(5): Article e0127348.10.1371/journal.pone.0127348 ↗
26. 10.1016/j.jbiotec.2010.01.01210.1016/j.jbiotec.2010.01.012 ↗
27. 10.1038/nprot.2008.22610.1038/nprot.2008.226 ↗
28. 10.1073/pnas.110780710810.1073/pnas.1107807108 ↗
29. Bierie B, Pierce SE, Kroeger C, Stover DG, Pattabiraman DR, Thiru P, Liu Donaher J, Reinhardt F, Chaffer CL, Keckesova Z, et al. Integrin-β4 identifies cancer stem cell-enriched populations of partially mesenchymal carcinoma cells. Proc Natl Acad Sci USA. 2017;114(12):E2337–E2346.10.1073/pnas.1618298114 ↗
30. 10.1016/j.bbrc.2007.10.06710.1016/j.bbrc.2007.10.067 ↗
31. 10.1002/ijc.3324910.1002/ijc.33249 ↗
32. Zhang B. CD73 promotes tumor growth and metastasis. Onco Targets Ther. 2012;1(1):67–70.
33. Lin Q, Peng S, Yang Y. Inhibition of CD9 expression reduces the metastatic capacity of human hepatocellular carcinoma cell line MHCC97-H. Int J Oncol. 2018;53(1):266–274.
34. Huan J, Gao Y, Xu J, Sheng W, Zhu W, Zhang S, Cao J, Ji J, Zhang L, Tian Y. Overexpression of CD9 correlates with tumor stage and lymph node metastasis in esophageal squamous cell carcinoma. Int J Clin Exp Pathol. 2015;8(3):3054–3061.
35. 10.1038/s41586-018-0040-310.1038/s41586-018-0040-3 ↗
36. 10.1016/j.tcb.2018.12.00110.1016/j.tcb.2018.12.001 ↗
37. Abulaiti A, Shintani Y, Funaki S, Nakagiri T, Inoue M, Sawabata N, Minami M, Okumura M. Interaction between non-small-cell lung cancer cells and fibroblasts via enhancement of TGF-β signaling by IL-6. Lung Cancer. 2013;82(2):204–213.10.1016/j.lungcan.2013.08.008 ↗
38. 10.1002/ar.2414710.1002/ar.24147 ↗
39. 10.1007/s10585-011-9394-810.1007/s10585-011-9394-8 ↗
40. Loh CY, Chai JY, Tang TF, Wong WF, Sethi G, Shanmugam MK, Chong PP, Looi CY. The E-cadherin and N-cadherin switch in epithelial-to-mesenchymal transition: Signaling, therapeutic implications, and challenges. Cells. 2019;8(10): Article 1118.10.3390/cells8101118 ↗
41. Gravdal K, Halvorsen OJ, Haukaas SA, Akslen LA. A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer. Clin Cancer Res. 2007;13(23):7003–7011.10.1158/1078-0432.CCR-07-1263 ↗
42. Liu L, Wu L, Shan D, Han B. Characterization and clinical relevance of PDGFRA pathway copy number variation gains across human cancers. Mol Gen Genomics. 2022;297(2):561–571.10.1007/s00438-022-01860-y ↗
43. Kosti A, de Araujo PR, Li WQ, Guardia GDA, Chiou J, Yi C, Ray D, Meliso F, Li YM, Delambre T, et al. The RNA-binding protein SERBP1 functions as a novel oncogenic factor in glioblastoma by bridging cancer metabolism and epigenetic regulation. Genome Biol. 2020;21(1): Article 195.10.1186/s13059-020-02115-y ↗
44. 10.1038/s41379-020-0550-z10.1038/s41379-020-0550-z ↗
45. 10.1002/cam4.124110.1002/cam4.1241 ↗
46. Usman S, Waseem NH, TKN N, Mohsin S, Jamal A, Teh MT, Waseem A. Vimentin is at the heart of epithelial mesenchymal transition (EMT) mediated metastasis. Cancers (Basel). 2021;13(19): Article 4985.10.3390/cancers13194985 ↗
47. Irani S, Dehghan A. The expression and functional significance of vascular endothelial-cadherin, CD44, and vimentin in oral squamous cell carcinoma. J Int Soc Prev Community Dent. 2018;8(2):110–117.10.4103/jispcd.JISPCD_408_17 ↗
48. Brown TC, Sankpal NV, Gillanders WE. Functional implications of the dynamic regulation of EpCAM during epithelial-to-mesenchymal transition. Biomol Ther. 2021;11(7): Article 956.
49. Terris B, Cavard C, Perret C. EpCAM, a new marker for cancer stem cells in hepatocellular carcinoma. J Hepatol. 2010;52(2):280–281.10.1016/j.jhep.2009.10.026 ↗
50. Shrestha N, Lateef Z, Martey O, Bland AR, Nimick M, Rosengren R, Ashton JC. Does the mouse tail vein injection method provide a good model of lung cancer? F1000Res. 2019;8: Article 190.10.12688/f1000research.17964.1 ↗